Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | CCR3 | P51677 | 2/20 | 0.48 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13800995 | 0.87 | TSHR (0.65) | TSHRGAAKMT2A | |
| SCHEMBL12157463 | 0.83 | TSHR (0.73) | TSHRRECQLKMT2AALDH1A1 | |
| Ethylene SCHEMBL8376514 | 0.79 | LMNA (0.54) | — | |
| SCHEMBL14538230 | 0.79 | HPGD (0.71) | ALDH1A1 | |
| SCHEMBL16002987 | 0.79 | HRH1 (0.53) | TSHRRECQLGAAHRH1CCR3 | |
| SCHEMBL13438736 | 0.78 | HPGD (0.54) | KMT2AALDH1A1 | |
| SCHEMBL22206744 | 0.77 | SLC9A1 (0.52) | TSHRRECQLGAAHRH1CCR3 | |
| SCHEMBL16000494 | 0.77 | HRH1 (0.51) | TSHRGAAHRH1CCR3SLC9A1 | |
| SCHEMBL13022078 | 0.77 | GPR183 (0.54) | TSHRALDH1A1 | |
| Ethylene SCHEMBL8380939 | 0.77 | HPGD (0.68) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| CN-1244576-C | Compound (I) | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | CN | disclosed |
| CN-1660839-A | Chemical compounds | ASTRAZENECA AB (SE) | 2005-08-31 | — | — | CN | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1274701-B1 | [1,4']-BIPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| CN-1433411-A | Compound (I) | ASTRAZENECA AB (SE) | 2003-07-30 | — | — | CN | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| EP-1274701-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
| WO-2001077101-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | TSHR 3436/4885RECQL 3757/4885GAA 2997/4885 |
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | TSHR 3393/4885RECQL 3264/4885GAA 2837/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | TSHR 3436/4885RECQL 3757/4885GAA 2997/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | TSHR 3436/4885RECQL 3757/4885GAA 2997/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | TSHR 3393/4885RECQL 3264/4885GAA 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.